PROCLIPI: a study aiming to identify factors important in predicting the outcome of cutaneous (skin) lymphomas, mycosis fungoides and Sezary syndrome

There is no treatment in this study. The researchers need your permission for your doctor to share information from your medical records for research.

Initial findings from this study have been published, but it is still recruiting new participants.

Purpose of study

The aim of the study is to gather the information needed to develop an improved ‘prognostic index’ for the rare cutaneous (skin) lymphomas, mycosis fungoides and Sézary syndrome. These are both types of T-cell lymphomas that start in the skin.

Cutaneous T-cell lymphomas can be very variable and many people only ever have a mild form that is not life-threatening and can be kept under control for many years. Only a few people go on to develop a more serious form.

A prognostic index is a group of factors that doctors look at when someone is first diagnosed. Looking at these together can help a specialist to tell which people are likely to do well and which not so well. In some conditions, including cutaneous T-cell lymphomas, the doctor can use a prognostic index to see who needs treating earlier or needs more intensive treatment and who doesn’t. You may hear doctors refer to these as high or low risk groups.

What is involved

If you join, your doctor sends details of your treatment, your test results and how you are to the study team for analysis. Your information is de-identified so you cannot be recognised (no name, date of birth or address is shared).

Who can enter

Your consultant can give you advice on whether this trial might be suitable for you.

Around 2000 people are needed for this trial.

You may be able to enter if:

  • You have been diagnosed with mycosis fungoides or Sézary syndrome in the past 6 months.

You will not be able to enter if:

  • You were diagnosed more than 6 months ago.

Further information

More information about this trial is available at